1. First-line nivolumab plus ipilimumab versus chemotherapy in patients with unresectable malignant pleural mesothelioma: 3-year outcomes from CheckMate 743
- Author
-
Peters, S., Scherpereel, A., Cornelissen, R., Oulkhouir, Y., Greillier, L., Kaplan, M.A., Talbot, T., Monnet, I., Hiret, S., Baas, P., Nowak, A.K., Fujimoto, N., Tsao, A.S., Mansfield, A.S., Popat, S., Zhang, X., Hu, N., Balli, D., Spires, T., Zalcman, G., CHUV, Lausanne (Departement d'Oncologie), Thérapies Laser Assistées par l'Image pour l'Oncologie - U 1189 (ONCO-THAI), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lille-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Erasmus University Medical Center [Rotterdam] (Erasmus MC), Service de pneumologie [CHU Caen], Université de Caen Normandie (UNICAEN), Normandie Université (NU)-Normandie Université (NU)-CHU Caen, Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN)-Tumorothèque de Caen Basse-Normandie (TCBN), Centre de Recherche en Cancérologie de Marseille (CRCM), Aix Marseille Université (AMU)-Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Hôpital Nord [CHU - APHM], Dicle University, Royal Cornwall Hospital, Service de Pneumologie [CHI Créteil], CHI Créteil, Institut de Cancérologie de l'Ouest [Angers/Nantes] (UNICANCER/ICO), UNICANCER, CRLCC René Gauducheau, Département d'oncologie médicale [Saint Herblain], UNICANCER-UNICANCER, Leiden University Medical Center (LUMC), Universiteit Leiden, Royal Marsden Hospital, Department of Energy and Process Engineering, Norwegian University of Science and Technology (NTNU), Bristol-Myers Squibb [Princeton], AP-HP - Hôpital Bichat - Claude Bernard [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), and Pulmonary Medicine
- Subjects
Adult ,PD-L1 ,[SDV]Life Sciences [q-bio] ,overall survival ,Mesothelioma, Malignant ,Hematology ,Ipilimumab ,Progression-Free Survival ,immune checkpoint inhibitors ,Nivolumab ,Oncology ,dual immunotherapy ,Antineoplastic Combined Chemotherapy Protocols ,Humans ,CTLA-4 ,first-line - Abstract
International audience; Background: In the phase III CheckMate 743 study (NCT02899299), first-line nivolumab plus ipilimumab significantly improved overall survival (OS) versus chemotherapy in patients with unresectable malignant pleural mesothelioma (MPM). We report updated data with 3-year minimum follow-up. Patients and methods: Adults with previously untreated, histologically confirmed, unresectable MPM and Eastern Cooperative Oncology Group performance status of = 3 years after discontinuation. Conclusions: With 3 years' minimum follow-up, nivolumab plus ipilimumab continued to provide long-term survival benefit over chemotherapy and a manageable safety profile, supporting the regimen as standard-of-care treatment for unresectable MPM, regardless of histology.
- Published
- 2022
- Full Text
- View/download PDF